Table 1. Baseline characteristics of the intention-to-treat population.
| Patients with carcinoid tumours (n=20) | Patients with pancreatic NETs (n=32) | |
|---|---|---|
| Age (years) | 63 (60–69) | 54.5 (45–69) |
|
| ||
| Sex | ||
| Male | 12 (60%) | 22 (69%) |
| Female | 8 (40%) | 10 (31%) |
|
| ||
| Performance status | ||
| 0 | 9 (45%) | 16 (50%) |
| 1 | 11 (55%) | 16 (50%) |
|
| ||
| Ethnic origin | ||
| White | 18 (90%) | 26 (81%) |
| Black | 0 (0%) | 2 (6%) |
| Hispanic | 2 (10%) | 3 (9%) |
| Native American | 0 (0%) | 1 (3%) |
|
| ||
| Grade | ||
| 1 | 15 (75%) | 23 (72%) |
| 2 | 5 (25%) | 9 (28%) |
|
| ||
| Carcinoid tumour primary site | ||
| Small bowel | 11 (55%) | ‥ |
| Rectum | 1 (5%) | ‥ |
| Lung | 1 (5%) | ‥ |
| Appendix | 1 (5%) | ‥ |
| Stomach | 1 (5%) | ‥ |
| Caecum | 1 (5%) | ‥ |
| Kidney | 1 (5%) | ‥ |
| Unknown | 3 (15%) | ‥ |
|
| ||
| Baseline chromogranin A increased | ||
| Yes | 16 (80%) | 15 (47%) |
| No | 3 (15%) | 15 (47%) |
| Unknown | 1 (5%) | 2 (6%) |
|
| ||
| Time from diagnosis (months) | 44 (17–65) | 31 (14–70) |
|
| ||
| Extent of disease at enrolment | ||
| Unresectable | 0 (0%) | 4 (13%) |
| Metastatic | 20 (100%) | 28 (88%) |
|
| ||
| Progression at enrolment | ||
| Yes | 17 (85%) | 21 (66%) |
| No | 3 (15%) | 11 (34%) |
|
| ||
| Previous therapy | ||
| SSA | 20 (100%) | 32 (100%) |
| Chemotherapy | 5 (25%) | 21 (66%) |
| Everolimus | 6 (30%) | 8 (25%) |
| Liver-directed therapy | 6 (30%) | 3 (9%) |
Data are median (IQR) or n (%) unless otherwise stated. SSA=somatostatin analogue (octreotide).